Rigel (RIGL) Upgraded to Buy: Here's Why
Portfolio Pulse from
Rigel Pharmaceuticals (RIGL) has been upgraded to a Zacks Rank #2 (Buy) due to growing optimism about its earnings prospects.
January 15, 2025 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) due to positive sentiment regarding its earnings prospects.
The upgrade to a Zacks Rank #2 (Buy) indicates increased confidence in Rigel's earnings potential, which is likely to positively influence its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100